Novel Vaccines

 

Ashley J. Birkett, Ph.D., Director, Preclinical Research & Development, The PATH Malaria Vaccine Initiative

Konstantin Chumakov, Ph.D., Chief, Laboratory of Method Development, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration (FDA)

Heather Davis, Ph.D., Senior Vice President, Vaccines Research Site Head, Ottawa Research Laboratories, Coley Pharmaceutical Group, a Pfizer company

Ofer Levy, M.D., Ph.D., Staff Physician, Infectious Diseases and Principal Investigator, Harvard Medical School/Children’s Hospital Boston

 Jan Vinjé, Ph.D., Head, National Calicivirus Laboratory, Gastroenteritis & Respiratory Viruses Laboratory Branch, Division of Viral Diseases (DVD), National Center for Immunizations and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention (CDC)

 


Nicholas I. Obiri, Ph.D., Senior Regulatory
Affairs Specialist, Office of Regulatory Affairs, National Institute of Allergy and Infectious Diseases (NIAID), NIH

Scientific Advisors
Carol Belzer, Ph.D., Microbiology, Biotechnology
Immunology & Diagnostics, US Dept of Agriculture
William Egan, Ph.D., Executive Director, PharmaNet Consulting
Michael Dekleva, Ph.D., Director, Worldwide Regulatory Group Vaccines, Merck & Co
Gregory M. Glenn, M.D., Chief Scientific Officer, IOMAI Corporation
Jamie K. Scott, Ph.D., Professor & Canada Research Chair in Molecular Immunity, Molecular Biology & Biochemistry, Simon Fraser UniversityMichael Dekleva, Ph.D., Director, Worldwide Regulatory Group Vaccines, Merck & Co

Selected Papers:
Adjuvants: Breathing New Life Into Vaccines
An interview with Nathalie Garcon, Pharm.D., Ph.D., Vice President,
Research and North America R&D,  Guano SmithKline Biologicals, 
by Malorye Allison, contributing editor, PharmaWeek 

A Novel Strategy to Mimic Discontinuous Protective Epitopes Using a Synthetic Scaffold
Robert Liskamp, Ph.D., Professor, Pharmaceutical Sciences and Chemistry, Utrecht University

To post questions to any of the authors, or to submit a paper or comment, please email:  vaccines@healthtech.com